Hangzhou Just Biotherapeutics lands $35 mln

China-based Hangzhou Just Biotherapeutics, a biotherapeutics platform company, has closed $35 million in Series B+ financing. Hillhouse Capital led the round with participation from return backers Temasek, Lilly Asia Ventures, ARCH Venture Partners, Taikang and BOCGI Zheshang Capital.

Source: Press Release